Phathom Non Current Liabilities Total from 2010 to 2025
| PHAT Stock | USD 7.95 0.37 4.45% |
Non Current Liabilities Total | First Reported 2019-06-30 | Previous Quarter 546.2 M | Current Value 558.6 M | Quarterly Volatility 190.3 M |
Check Phathom Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Phathom Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 15.9 M, Depreciation And Amortization of 635.5 K or Interest Expense of 75.6 M, as well as many indicators such as Price To Sales Ratio of 8.82, Dividend Yield of 0.0 or Days Sales Outstanding of 243. Phathom financial statements analysis is a perfect complement when working with Phathom Pharmaceuticals Valuation or Volatility modules.
Phathom | Non Current Liabilities Total | Build AI portfolio with Phathom Stock |
Latest Phathom Pharmaceuticals' Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Phathom Pharmaceuticals over the last few years. It is Phathom Pharmaceuticals' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Phathom Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
Phathom Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 121,875,031 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 170.54 | |
| Mean Deviation | 161,669,422 | |
| Median | 0.00 | |
| Standard Deviation | 207,842,196 | |
| Sample Variance | 43198.4T | |
| Range | 573.5M | |
| R-Value | 0.79 | |
| Mean Square Error | 17179.5T | |
| R-Squared | 0.63 | |
| Significance | 0.0002 | |
| Slope | 34,618,196 | |
| Total Sum of Squares | 647975.7T |
Phathom Non Current Liabilities Total History
About Phathom Pharmaceuticals Financial Statements
Phathom Pharmaceuticals shareholders use historical fundamental indicators, such as Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Although Phathom Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Phathom Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Phathom Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 546.2 M | 573.5 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.